Tangram Doses First Participant in Phase 1 Trial of Bleeding Disorder Drug TGM-148

• Tangram Therapeutics dosed the first healthy volunteer in a Phase 1 trial of TGM-148, its investigational RNAi treatment for bleeding disorders.
• The single-ascending-dose study will assess safety and pharmacology, with initial data expected in 2027.
• Von Willebrand disease is the planned first indication, with potential expansion into other rare bleeding disorders.
• TGM-148 targets Protein Z-dependent Protease Inhibitor to enhance clot formation, with an anticipated regimen of four or fewer subcutaneous doses annually.
• The treatment is Tangram’s second drug candidate to enter clinical trials in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tangram Therapeutics plc published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.